US Patent

US8795725 — GABA analog prodrug sustained release oral dosage forms

Method of Use · Assigned to XenoPort Inc · Expires 2029-06-10 · 3y remaining

Vulnerability score 73/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent discloses sustained release oral dosage forms of a gabapentin prodrug, specifically 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid.

USPTO Abstract

Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(Î±-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective.

Drugs covered by this patent

Horizant (GABAPENTIN ENACARBIL) · Azurity

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1231`	—	Horizant
`U-1231`	—	Horizant

Patent Metadata

Patent number: US8795725
Jurisdiction: US
Classification: Method of Use
Expires: 2029-06-10
Drug substance claim: No
Drug product claim: Yes
Assignee: XenoPort Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.